Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans

Human cyclooxygenase-2 cDNA.

Timothy Hla, Karen M. Neilson · Proceedings of the National Academy of Sciences · 1992 · 1.5K citations · Full text

Immunology, Cox-2 Transcript, Redox Biology +21

Cyclooxygenase-1 and Cyclooxygenase-2 Selectivity of Widely Used Nonsteroidal Anti-Inflammatory Drugs

Byron Cryer, Mark Feldman · The American Journal of Medicine · 1998 · 759 citations · Full text

Inflammation, Anti-inflammatory, Medicine +8

Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects

Carlo Patrono, Giovanni Ciabattoni, E Pinca et al. · Thrombosis Research · 1980 · 647 citations

Thrombopoiesis, Thrombosis, Healthy Subjects +11

Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases.

Paola Patrignani, Maria R. Panara, Anita Greco et al. · Journal of Pharmacology and Experimental Therapeutics · 1994 · 518 citations

Rofecoxib [Vioxx, MK-0966; 4-(4′-Methylsulfonylphenyl)-3-phenyl-2-(5 H)-furanone]: A Potent and Orally Active Cyclooxygenase-2 Inhibitor. Pharmacological and Biochemical Profiles

Chi‐Chung Chan, S. Boyce, Christine Brideau et al. · Journal of Pharmacology and Experimental Therapeutics · 1999 · 397 citations · Full text